Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north ...

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

This was the stock's second consecutive day of losses.

Coming up: a key tariffs deadline, the Fed’s interest-rate decision, the July jobs report, fresh inflation data, and earnings from companies including Microsoft, Meta, Apple and Amazon.

First-line treatment with the monoclonal antibody is associated with more patients achieving robust clinical response at 3 months vs standard of care, but by 6 months no advantage remained.